For immediate release
18 September 2018
Evgen Pharma plc
("Evgen" or "the Company")
The clinical significance of SFX-01
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is holding an Investor Symposium for investors and analysts today at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
The Investor Symposium, titled "The clinical significance of SFX-01" will begin at 9.15am. If you wish to attend the event, please contact Buchanan on 0207 466 500 or email [email protected]
The presentations from the event will be made available on the Company website, www.evgen.com. No new material trading information will be disclosed.
Evgen Pharma plc
Dr Stephen Franklin, CEO
Richard Moulson, CFO
c/o +44 (0) 20 7466 5000
| || |
Mark Court, Sophie Wills, Tilly Abraham
+44 (0) 20 7466 5000
| || |
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry Beaney (Corporate Finance)
Rob Rees (Corporate Broking)
+44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång
+44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.